ArticleInternational journal of nanomedicine2026
Developing a Better Hepatocellular Carcinoma Treatment: AlEu MOF Nanoparticles Enhance Microwave Thermal Ablation and Synergistically Activate the cGAS-STING Pathway.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To address the high recurrence rate of hepatocellular carcinoma (HCC) following microwave ablation (MWA) therapy, this study develops aluminum-europium metal-organic framework (AlEu MOF) nanoparticles that enhance MWA efficacy by physically improving thermal ablation and activating cyclic GMP-AMP (cGAMP) synthase-stimulator of interferon genes (cGAS-STING)-mediated antitumor immunity. Methods: AlEu MOF nanoparticles were synthesized via a one-pot hydrothermal method and characterized for physicochemical properties. Biocompatibility and in vitro cell-killing efficacy in combination with MWA were evaluated in Hepa1-6 cell lines. Immunostimulatory capacity was assessed by measuring activation markers of the cGAS-STING pathway. In vivo antitumor efficacy was investigated in a Hepa1-6 subcutaneous tumor-bearing mouse model, with monitoring of tumor growth, intratumoral temperature elevation, serum levels of cGAS-STING pathway downstream effectors, and treatment safety. Results: AlEu MOF nanoparticles demonstrated excellent biocompatibility and hemocompatibility. In combination with MWA, AlEu MOF significantly enhanced thermal efficiency within tumors, resulting in superior tumor growth inhibition compared with MWA alone. Mechanistically, the enhanced thermal ablation triggered mitochondrial damage and downstream cGAS-STING pathway activation, as evidenced by elevated serum levels of key downstream cytokines (IFN-γ, IL-6 and TNF-α) in the combination therapy group. No significant hepatorenal toxicity or major organ damage was observed throughout the treatment period. Conclusion: The AlEu MOF nanoparticles potentiate MWA therapy through a dual synergistic mechanism: enhanced thermal ablation serves as the upstream trigger for cGAS-STING activation, while europium ions simultaneously amplify the STING signaling output, together converting local thermal ablation into systemic antitumor immunity. This synergistic strategy offers a promising approach for enhancing both local tumor ablation and systemic antitumor immunity in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.